Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study

The rarity of mixed phenotype acute leukemia (MPAL) has precluded adequate data to incorporate minimal residual disease (MRD) monitoring into therapy. Fluidity in MPAL classification systems further complicates understanding its biology and outcomes; this includes uncertainty surrounding the impact...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia 2020-07, Vol.34 (7), p.1741-1750
Main Authors: Oberley, Matthew J, Raikar, Sunil S, Wertheim, Gerald B, Malvar, Jemily, Sposto, Richard, Rabin, Karen R, Punia, Jyotinder N, Seif, Alix E, Cahen, Viviane C, Schore, Reuven J, Luca, Dragos C, Guinipero, Terri, Woods, William G, O'Gorman, Maurice R G, Orgel, Etan
Format: Article
Language:English
Subjects:
Acute leukemia
Acute lymphoblastic leukemia
Analysis
Cancer
Child
Children
Classification
Classification systems
Clinical trials
Cohort analysis
Cohort Studies
Diagnostic systems
Diseases
Female
Fluidity
Follow-Up Studies
Genetic aspects
Health aspects
Hematopoietic Stem Cell Transplantation - adverse effects
Hematopoietic Stem Cell Transplantation - mortality
Humans
Induction Chemotherapy - mortality
Induction therapy
Leukemia
Leukemia - classification
Leukemia - mortality
Leukemia - pathology
Leukemia - therapy
Lymphatic leukemia
Male
Minimal residual disease
Neoplasm, Residual - epidemiology
Neoplasm, Residual - mortality
Neoplasm, Residual - pathology
Oncology, Experimental
Patients
Pediatrics
Phenotype
Phenotypes
Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality
Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology
Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy
Prognosis
Remission
Survival
Survival Rate
Therapy
Transplantation
United States - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The rarity of mixed phenotype acute leukemia (MPAL) has precluded adequate data to incorporate minimal residual disease (MRD) monitoring into therapy. Fluidity in MPAL classification systems further complicates understanding its biology and outcomes; this includes uncertainty surrounding the impact of shifting diagnostic requirements even between iterations of the World Health Organization (WHO) classification. Our primary objective was to address these knowledge gaps. To do so, we analyzed clinicopathologic features, therapy, MRD, and survival in a centrally-reviewed, multicenter cohort of MPAL uniformly diagnosed by the WHO classification and treated with acute lymphoblastic leukemia (ALL) regimens. ALL induction therapy achieved an EOI MRD negative (
ISSN:0887-6924
1476-5551
DOI:10.1038/s41375-020-0741-0